AccuStem Sciences, Inc. Announces Acquisition of Proprietary MSC Lung Cancer Screening Test

Core Insights - AccuStem Sciences, Inc. is pursuing a strategic commercialization plan to launch the proprietary microRNA Signature Classifier (MSC) test in the US by 2026 [1][3] - The MSC test aims to enhance the accuracy of lung cancer screening by evaluating 24 micro RNAs, thereby improving the diagnostic performance of low-dose computed tomography (LDCT) [2][3] Company Overview - AccuStem is a clinical stage diagnostics company focused on improving outcomes for cancer patients through proprietary molecular testing [5] - The company plans to address unmet clinical needs from cancer screening to treatment and monitoring by exploring novel disease pathways [5] Acquisition Details - AccuStem has acquired the rights to the MSC test, with the consideration being 3,750,000 common shares issued to certain secured creditors and interest holders [4] - The acquisition includes the transfer of all rights, title, and interest in the intellectual property related to the MSC test [4] Clinical Impact - The MSC test, when used in conjunction with LDCT, is expected to significantly reduce false positives by five-fold compared to LDCT alone, leading to better patient outcomes and lower healthcare costs [3] - Data indicates that patients who are MSC+/LDCT+ have a cumulative lung cancer incidence 30-fold higher than those who are MSC-/LDCT-, allowing for safer screening intervals [3]